Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

48,799 stories, page 70 of 814

Advanced search

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

Yahoo FinanceOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal

The Manila TimesOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.

Stock TitanOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

OpenAI acquires biotech startup Orchestra Bio

The Daily StarOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda approves new weight loss drug

emyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure

TipRanksOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

health news today fda approval weight loss drug

emyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda concerns unapproved glp-1 drugs used for weight loss

emyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Business WireOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Indonesia, Russia explore drug technology transfers to cut imports

ANTARA NewsOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda weight loss drug news today october 2025

emyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

The fine print on America’s drug deals with China | Opinion

The Providence JournalOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

new fda approved diabetes drug for weight loss

ΕΜΥOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?

The Motley FoolOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Is Tango Therapeutics (TNGX) Undervalued As Phase 3 Plans Follow Strong Trial Data?

Simply Wall StreetOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda concerns unapproved glp-1 drugs used for weight loss 2025

ΕΜΥOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda concerns unapproved glp-1 drugs retatrutide weight loss

BusinessWorld OnlineOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

106,238 Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLC

MarketBeatOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda concerns unapproved glp-1 drugs retatrutide weight loss

ΕΜΥOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

The Motley FoolOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

MarketBeatOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

Yahoo FinanceOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

RELATIVITY-047’s Five-Year Data Just Made LAG-3 Biomarker Selection a Clinical Trial Design Imperative

The Clinical Trial VanguardOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Nymox Pharmaceutical Corp. Estimates – OTC:NYMXF

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda concerns unapproved glp 1 drugs weight loss official

ΕΜΥOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

South Korea's Hanmi Pharmaceutical Faces Special Audit Demand From Lim Jong-yoon Camp as Control Fight Escalates

BigGo FinanceOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical (TSE:4519) Stock May Be Cheap On Cash Flow

Yahoo FinanceOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Indrayani Biotech Ltd. Estimates – BSE:INDRANIB

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

new weight loss drug awaiting fda approval

ΕΜΥOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer

The Clinical Trial VanguardOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

BioNTech-BMS Phase 2 lung cancer trial shows 36.7% response | BNTX Stock News

Stock TitanOriginal source

🇺🇸Oct 25Industrybristolmyers2016ir.q4web.comTier 3 · Secondary coverage

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Bristol-Myers Squibb NewsOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Veradermics (NYSE:MANE) - Stock Analysis

Simply Wall StreetOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Tianjin Lisheng Pharmaceutical Co., Ltd. Class A Estimates – SZSE:002393

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

the fda issued warnings for misleading compounded weight-loss drug ads

emyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda approves new weight loss drug

emyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In Trial

Health and MeOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA suspends licences of seven eateries including Ottoman Cafe, Bharat Canteen over food safety violations

LivemintOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

‘Designer baby’ start-ups test limits of biotech taboo

Financial TimesOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Hanmis next obesity drug candidate gets WHO name, with Eppe poised for launch

Aju PressOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

Seeking AlphaOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Purple Biotech Ltd. Estimates – TASE:PPBT

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda weight loss drugs harder to get

ΕΜΥOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Krystal Biotech (KRYS) Tests Its Multiproduct Story After Recent Pullback

Simply Wall StreetOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

China's Pharma Licensing Deals Top $138.8 Billion, With $150.9 Billion in Sight This Year

BigGo FinanceOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

new fda approved weight loss drugs

BusinessWorld OnlineOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

NKGen Biotech Inc. Estimates – OTC:NKGNW

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

KYORIN Pharmaceutical Co.,Ltd. Estimates – TSE:4569

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

recent fda approved weight loss drugs

BusinessWorld OnlineOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda approved prescription weight loss drugs 2026

BusinessWorld OnlineOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

fda approved weight loss drug 2019

BusinessWorld OnlineOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Kangmei Pharmaceutical Co., Ltd Class A Estimates – SSE:600518

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Ultragenyx Pharmaceutical (RARE) Could Be 40% Undervalued As Turnaround Doubts Persist

Simply Wall StreetOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Saudi Pharmaceutical Industries & Medical Appliances Corp. Estimates – TADAWUL:2070

TradingViewOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

U.S. Tightens Curbs on Chinese Investment in AI, Biotech

Seoul Economic DailyOriginal source

🌍Oct 25discoverynews.google.comTier 3 · Aggregated media

Qingdao Vland Biotech INC. Class A Estimates – SSE:603739

TradingViewOriginal source

🇪🇺Oct 25Researcheuropepmc.orgTier 2 · Direct publisher

Safety and Efficacy of Poly‐L‐Lactic Acid Filler (HYZ vs. Löviselle) Injection for Nasolabial Fold Correction: A Double‐Blind, Non‐Inferiority, Randomized, Controlled Trial

Europe PMCOriginal source

🇪🇺Oct 25Researcheuropepmc.orgTier 2 · Direct publisher

Symmetric Centipolar Normalized Score (SCeNS): A standardization framework for fluid marker cross-comparability in Alzheimer's disease.

Europe PMCOriginal source

🇪🇺Oct 25Researcheuropepmc.orgTier 2 · Direct publisher

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.

Europe PMCOriginal source

🇪🇺Oct 25Researcheuropepmc.orgTier 2 · Direct publisher

Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease.

Europe PMCOriginal source